These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 15555997)
1. Finding their groove; bifunctional molecules arrest growth of cancer cells. Mapp AK Chem Biol; 2004 Nov; 11(11):1480-2. PubMed ID: 15555997 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568 [TBL] [Abstract][Full Text] [Related]
3. Development of vorinostat: current applications and future perspectives for cancer therapy. Richon VM; Garcia-Vargas J; Hardwick JS Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442 [TBL] [Abstract][Full Text] [Related]
5. Development of histone deacetylase inhibitors for cancer treatment. Marchion D; Münster P Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177 [TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Riester D; Hildmann C; Schwienhorst A Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297 [TBL] [Abstract][Full Text] [Related]
9. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693 [TBL] [Abstract][Full Text] [Related]
10. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Comoglio PM; Giordano S; Trusolino L Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928 [TBL] [Abstract][Full Text] [Related]
11. Livin/ML-IAP as a new target for cancer treatment. Liu B; Han M; Wen JK; Wang L Cancer Lett; 2007 Jun; 250(2):168-76. PubMed ID: 17218055 [TBL] [Abstract][Full Text] [Related]
12. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222 [TBL] [Abstract][Full Text] [Related]
13. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. Hess-Stumpp H; Bracker TU; Henderson D; Politz O Int J Biochem Cell Biol; 2007; 39(7-8):1388-405. PubMed ID: 17383217 [TBL] [Abstract][Full Text] [Related]
14. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective. Perry WL; Weitzman A Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991 [TBL] [Abstract][Full Text] [Related]
16. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Low PS; Henne WA; Doorneweerd DD Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Grønbaek K; Treppendahl M; Asmar F; Guldberg P Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362 [TBL] [Abstract][Full Text] [Related]
18. Novel approaches on epigenetics. Papait R; Monti E; Bonapace IM Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872 [TBL] [Abstract][Full Text] [Related]
19. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Mai A; Altucci L Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076 [TBL] [Abstract][Full Text] [Related]